SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense investor backlash following the abrupt cancellation of a major contract with Marvell, which was triggered by the CFO's alleged violation of a confidentiality agreement. The community is sharply divided between those calling for immediate leadership changes to restore credibility and those attempting to buy the dip, citing the company's underlying photonics technology as a reason for long-term optimism.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it hits new record highs, fueled by intense institutional demand and optimistic sentiment surrounding its dominance in the AI infrastructure cycle. Investors are actively debating the sustainability of its multi-trillion-dollar valuation, with bulls pointing to fundamental growth while skeptics monitor for potential signs of overheating.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as a momentum-driven play, with investors closely watching for signs of a short squeeze amid high volatility and active sentiment regarding potential price swings. The community is heavily focused on the stock's thin float and the influence of speculative trading patterns, frequently comparing its aggressive moves to previous market runners.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid investor excitement over potential merger activity and a significant acquisition plan involving European Lithium, which investors believe could consolidate control of its Greenland-based Tanbreez project. The community is focused on the strategic importance of the company's rare earth assets for U.S. and European defense supply chains, fueling a debate between long-term bulls anticipating a supply-side squeeze and short-term traders reacting to volatility and corporate structure updates.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently trending as a prominent infrastructure play in the AI hardware sector, with investors closely watching for earnings-driven volatility after the company's recent strategic collaborations, such as the AMD Helios platform partnership. The community is actively debating the company's valuation relative to its hyperscaler demand, with many focused on whether this quarter will trigger a major breakout or another round of consolidation as it navigates significant institutional interest.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the community debates its progress in the eVTOL sector, specifically highlighting its recent demonstration flights in New York City and its ongoing collaboration with Toyota for manufacturing scale. Investors are actively discussing the company's long-term potential versus execution risks, with some closely monitoring the technical price action and options activity as catalysts for the stock's next move.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently under intense scrutiny from the community following the release of Phase 3 results for its CRISPR-based HAE therapy, which met primary and secondary endpoints but has sparked debate over efficacy compared to existing oral alternatives. Investors are actively discussing the stock's high short interest, the potential for a short squeeze, and concerns over future dilution via the company's ATM facility, leaving sentiment sharply divided between those betting on a long-term breakthrough and those wary of clinical and commercial risks.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing intense volatility and volume-driven interest as investors monitor a tight effective float and speculate on potential buyout scenarios or strategic partnerships. The community remains deeply divided, with bullish participants pointing to recent institutional accumulation and clinical data, while others express skepticism regarding management's communication history and the potential for near-term equity dilution.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to a series of strategic acquisitions, including the purchase of tokens.com/ and plans to acquire F9 Brands, as the company pivots toward a comprehensive home services and retail ecosystem. While some in the community express optimism about the potential for a turnaround and synergy, others remain deeply skeptical, citing concerns over historical cash burn, dilution, and the sustainability of the company's new business model.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is currently trending as investors weigh the potential of a massive stock buyback and dividend hike against persistent concerns regarding smartphone market headwinds and loss of key modem business. The community is actively debating whether the stock represents a deep-value opportunity for AI-driven edge computing or if it remains a value trap due to structural revenue risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Edesa Biotech from a "sell" rating to a "hold" rating in a research note on Sunday...

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,411,103 shares...

Best Biotech Stocks To Follow Today - March 7th

Danaher, Moderna, Vertex Pharmaceuticals, argenex, Iovance Biotherapeutics, Edesa Biotech, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Pardeep Nijhawan Purchases 10,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Thursday, March 5th. The shares were purchased at an...

Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were acquired at an average...

Edesa Biotech (NASDAQ:EDSA) CEO Buys $36,300.00 in Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan acquired 10,000 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was acquired at an average...

Pardeep Nijhawan Acquires 30,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 30,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were purchased at an...

<ul class="summary-bullets"><li>The company on Tuesday reported results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.</li><li>Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said.&nbsp;</li><li>The company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities, the CEO said.</li></ul>Shares of Edesa Biotech, Inc. jumped 76% on Tuesday after the company announced that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.Acute respiratory distress syndrome (ARDS) is a life-threatening, rapid-onset lung failure caused by severe inflammation, which fills the air sacs with fluid and restricts oxygen absorption.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/24/3243711/0/en/Edesa-Biotech-Reports-Additional-Positive-Results-from-Phase-3-Paridiprubart-Study.html">reported</a> results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.Edesa Biotech said that its experimental drug paridiprubart demonstrated statistically significant reduction in 28-day mortality in the full population to 24% from 33%.Further, treatment benefits were consistent across severity groups and in patients with serious comorbidities. Overall rates of adverse events, serious adverse events, infections, and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said. &nbsp;<h2 class="st-heading-2">CEO Expresses Optimism</h2>“The consistency of mortality reduction and clinical improvement across all 278 randomized patients, including less severe patients as well as those with ARDS complicated by acute kidney injury, sepsis and pneumonia, underscores the versatility and transformative potential of paridiprubart to address multiple critical unmet medical needs,” said CEO Par Nijhawan.The chief also added that the company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities which could potentially accelerate development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user said that they are now waiting for that “first real surge” in stock price.<stembedurl>https://www.stocktwits.com/topstockalerts/message/645761015</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has dropped 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ark-cathie-wood-rebuts-citrini-ai-thought-piece/cZRw3pOR4Cp">ARK’s Cathie Wood Rebuts Citrini AI Thought Piece, Predicts Opportunities After Near-Term Disruptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did EDSA Stock Rally More Than 70% Today?

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.

Equity

Earnings

Fed / Macro data

Headlines / Geopolitics

Other (drop a comment)

What will be the main driver of the market this week?

Stocktwits

Stocktwits Polls

Traders are intensely speculating on a potential acquisition of the company by major pharmaceutical firms given recent clinical success.

Investors are closely watching the extremely low 3.3 million share float as a catalyst for high volatility and potential rapid price appreciation.

Sentiment is highly bullish as the stock maintains momentum while successfully breaking into the double-digit price range.

Market attention is driven by positive Phase 3 trial data regarding their ARDS treatment, positioning it as a significant biotech asset.

Persistent concerns regarding potential share dilution remain a talking point among traders watching for a cash-raising event.

EDSA
Edesa Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EDSA News

EDSAEdesa Biotech Inc